12th Asian Biologics and Biosimilars Congress | Tokyo, Japan

World’s largest Pharmaceutical Meet at Asian Biosimilars 2018 in Tokyo, Japan

LONDON, UK, 2018-May-03 — /EPR Network/ — Conferenceseries llc LTD invites you to attend the 12th Asian Biologics and Biosimilars Congress one of its remarkable Pharmaceutical conferences, to be held during August 20-21, 2018 in Tokyo, Japan.

Join your peers around the world focused on learning about Biologics and Biosimilars related advances, which is your single best opportunity to reach the largest assemblage of participants from the Biosimilars community, conduct demonstrations, distribute information, meet with current and potential professionals, make a splash with new research works, and receive name recognition at this 2-day event. World-renowned speakers, the most recent research, advances, and the newest updates in Biologics and Biosimilars are hallmarks of this conference.

The conference will feature keynote presentations by top scientists, researchers, business development managers, CEOs, directors, IP Attorneys, Regulatory Officials and CROs from around the world. Asif Mahmood, Disease Area Cluster Lead (PEH SSRM), Pfizer, USA, Michel Mikhail, Senior VP, International Expert in Biosimilars, USA, Pierre A Morgon, CEO MRGN Advisors – Certified CxO, Vaccitech Limited, Switzerland, Devrim Satik, Global Regulatory Affairs AMESA ME Zone Head, Sanofi, Turkey, Jianguo Yang, CEO, TAYU Huaxia biotech medical group, Beijing, China, Divya Chadha Manek, Head of Business Development, NIHR Clinical Research Network, United Kingdom, Tucker Herbert, Manager, ZS Associates, USA, T. Santha Raju, Sr. Director & Head, MedImmune, USA, Kurt Karst, Attorney at Hyman, Phelps & McNamara, P.C., USA will present their lectures during the conference.

With the approval of second biosimilar by the USFDA-Inflectra, the biosimilars market is owned to experience an exponential growth over the coming few years. Many biologics products are making their entry in the pharma market and experiencing a notable rise in their usage over the conventional medications.

The global Biosimilars market (Follow-On-Biologics) is expected to reach $26.5Billion by 2020 growing at a CAGR of 49.1% from 2015 to 2020 whereas the global biosimilars market alone  is expected to reach $6.22 Billion by 2020  from  $2.29 Billion in  2015, at a  compound annual growth rate ( CAGR )of 22.1% from 2015 to 2020.

Conference Highlights:

• 300+ Participation (70 Industry: 30 Academia)
• 5+ Keynote Speakers
• 50+ Plenary Speakers
• 20+ Exhibitors
• 14 Innovative Educational Sessions
• 5+ Workshops
• B2B Meetings

Target Audience:

Directors, CEO’s of Organizations, Business Development Managers, Chief Scientific Officers, R&D Researchers from Biosimilar and Biologics Industries, Professors, Associate Professors, Assistant Professors, PhD Scholars, Patent Attorneys, Intellectual Property Attorneys, Investment Analysts, Association, Association presidents and professionals, Noble laureates in Health Care and Medicine, Bio instruments Professionals, Bio-informatics Professionals, Software development companies, Research Institutes and members, Supply Chain companies, Manufacturing Companies, CRO and DATA management Companies, Training Institutes, Business Entrepreneurs.

The choice of city as a venue for the event has been further validated by the fact that Japan’s pharmaceuticals market ranks 3rd globally, and is growing at a compound annual growth rate (CAGR) of 3.4%. While biopharmaceuticals account for around 30% of overall global drug sales, the products only make up 10% of sales in Japan. As such, rapid growth is projected for the Japanese biopharmaceutical market. The biosimilars market is also a rapidly growing one, with a variety of products currently under development.

If you would like to know more information about this conference, Contact: Victorya Jones

Tel.: +1 7025085200

Email:  victorya_jones@protonmail.com

Website: https://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific